Saadeldin is a manufacturing specialist at FinVector (affiliate company to Ferring Pharmaceuticals). He holds a master's degree in molecular medicine and bioinformatics from the University of Eastern Finland.
Current research
Saadeldin is currently developing the manufacturing process of a gene-therapy-based drug for bladder cancer.
Future research vision
Key publications
Serobyan, V et al. Transcriptional Adaptation in Caenorhabditis Elegans. Elife, 2020.
